BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 14623051)

  • 1. Expression and function of TNF-family proteins and receptors in human osteoblasts.
    Bu R; Borysenko CW; Li Y; Cao L; Sabokbar A; Blair HC
    Bone; 2003 Nov; 33(5):760-70. PubMed ID: 14623051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor family receptors regulating bone turnover: new observations in osteoblastic and osteoclastic cell lines.
    Robinson LJ; Borysenko CW; Blair HC
    Ann N Y Acad Sci; 2007 Nov; 1116():432-43. PubMed ID: 17646260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
    Koyama S; Koike N; Adachi S
    J Cancer Res Clin Oncol; 2002 Feb; 128(2):73-9. PubMed ID: 11862476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
    Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
    Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of the expression of CD95 ligand, receptor activator of nuclear factor-kappa B ligand (RANKL), TNF-related apoptosis-inducing ligand (TRAIL), and TNF-alpha during T cell activation.
    Wang R; Zhang L; Zhang X; Moreno J; Luo X; Tondravi M; Shi Y
    J Immunol; 2001 Feb; 166(3):1983-90. PubMed ID: 11160247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Death receptor-3 mediates apoptosis in human osteoblasts under narrowly regulated conditions.
    Borysenko CW; García-Palacios V; Griswold RD; Li Y; Iyer AK; Yaroslavskiy BB; Sharrow AC; Blair HC
    J Cell Physiol; 2006 Dec; 209(3):1021-8. PubMed ID: 16986165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT-6 mediates TRAIL induced RANK ligand expression in stromal/preosteoblast cells.
    Sundaram K; Sambandam Y; Balasubramanian S; Pillai B; Voelkel-Johnson C; Ries WL; Reddy SV
    Bone; 2015 Feb; 71():137-44. PubMed ID: 25445452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts.
    Rifas L; Arackal S; Weitzmann MN
    J Cell Biochem; 2003 Mar; 88(4):650-9. PubMed ID: 12577299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis.
    Atkins GJ; Bouralexis S; Evdokiou A; Hay S; Labrinidis A; Zannettino AC; Haynes DR; Findlay DM
    Bone; 2002 Oct; 31(4):448-56. PubMed ID: 12398939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells.
    Miyashita T; Kawakami A; Nakashima T; Yamasaki S; Tamai M; Tanaka F; Kamachi M; Ida H; Migita K; Origuchi T; Nakao K; Eguchi K
    Clin Exp Immunol; 2004 Aug; 137(2):430-6. PubMed ID: 15270863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTH differentially regulates expression of RANKL and OPG.
    Huang JC; Sakata T; Pfleger LL; Bencsik M; Halloran BP; Bikle DD; Nissenson RA
    J Bone Miner Res; 2004 Feb; 19(2):235-44. PubMed ID: 14969393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
    Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
    J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of tumor necrosis factor- alpha -related apoptosis-inducing ligand and its proapoptotic receptors is down-regulated during gastric infection with virulent cagA+/vacAs1+ Helicobacter pylori strains.
    Neu B; Rad R; Reindl W; Neuhofer M; Gerhard M; Schepp W; Prinz C
    J Infect Dis; 2005 Feb; 191(4):571-8. PubMed ID: 15655781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells.
    Zhang XD; Franco AV; Nguyen T; Gray CP; Hersey P
    J Immunol; 2000 Apr; 164(8):3961-70. PubMed ID: 10754286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of osteoblast gap junction connectivity by serum, TNFalpha, and TRAIL.
    Sharrow AC; Li Y; Micsenyi A; Griswold RD; Wells A; Monga SS; Blair HC
    Exp Cell Res; 2008 Jan; 314(2):297-308. PubMed ID: 18022159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
    Kumamoto H; Ooya K
    J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
    Kim K; Fisher MJ; Xu SQ; el-Deiry WS
    Clin Cancer Res; 2000 Feb; 6(2):335-46. PubMed ID: 10690508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.